Biofire Diagnostics LLC

Biofire Diagnostics LLC, a foreign-owned for-profit biotechnology company headquartered in Salt Lake City, Utah, manufactures and supplies molecular diagnostic reagents, testing systems, and related equipment to federal healthcare agencies as a prime contractor operating entirely in full-and-open competition with no set-aside designations. The company is a child entity of Biomerieux Inc., a manufacturer of in-vitro diagnostic substances and laboratory instruments.

Biofire Diagnostics specializes in syndromic infectious disease detection through its FilmArray diagnostic platform and associated molecular pathogen detection panels and reagents. The vendor delivers firm fixed-price diagnostic testing products and maintenance services across respiratory, gastrointestinal, bloodstream infection, meningitis, and other infectious disease test panels to federal healthcare customers. Representative work includes a $655,225 BPA call from Department of Veterans Affairs Veterans Integrated Service Network 19 for BioFire reagents and extended warranty maintenance for facilities in Grand Junction and Salt Lake City (awarded September 2025), a $2.47 billion firm fixed-price purchase order from the Defense Health Agency for testing kits and panels covering bloodstream infections, COVID-19, meningitis, and encephalitis (awarded April 2022, completing April 2026), and a $377,488.17 purchase order from the Indian Health Service for cost-per-test and supplies to the laboratory department at Chinle Comprehensive Health Care Facility in Arizona (awarded July 2023, through September 2025).

Customer concentration is heavily weighted toward the Department of Veterans Affairs across multiple Veterans Integrated Service Networks. The top five customers by potential value account for approximately 48% of the vendor's combined potential value, led by VA VISNs 8, 15, 1, and 21, supplemented by the Defense Health Agency. By award count, VA VISN 10, VISN 23, VISN 6, VISN 2, and VISN 21 dominate (36% of awards), reflecting Biofire's deep penetration across the VA's regional healthcare networks. The two rankings reveal a concentration shift toward higher-dollar single orders rather than transactional volume at certain networks.

Biofire's federal work flows almost entirely through the GSA Federal Supply Schedule contract for In-Vitro Diagnostics, Reagents, and Tests (FSS-65-VII), under which 707 task orders worth $258.3 million have been issued. The vendor also holds standalone BPAs with VA VISN 19 ($4.83 million through September 2025), VISN 10 ($809,835 through September 2027), and single-award blanket purchase agreements with VA VISN 23 ($749,138 through September 2024), VA VISN 4 ($116,005 through September 2027), the Indian Health Service ($477,260 through August 2026), and indefinite delivery vehicles with VA VISN 2 ($1.24 million through September 2026) and VA VISN 10 ($2.75 million through December 2026). The GSA Schedule carries the overwhelming majority of Biofire's ordering weight and serves as the primary vehicle for federal healthcare agencies to procure diagnostic products on an as-needed basis.

Activity has declined significantly. The vendor received 94 awards in 2022, 46 in 2023, 30 in 2024, 7 in 2025, and 3 in 2026—a sharp year-over-year contraction. Twenty awards (combined potential value $10.4 million) reach ultimate completion within the next twenty-four months, representing moderate recompete exposure. SCI reporting shows minimal service-contract activity: only $1.1 million invoiced in FY2023 across zero reported FTEs, with no SCI-reportable invoicing in FY2022 or FY2024. This reflects that Biofire's federal revenue consists predominantly of goods (reagents, panels, diagnostic equipment) and product-based task orders rather than labor-hour service contracts above the SCI $150,000 threshold.

The vendor operates as a pure prime contractor—933 of 934 total awards are prime contracts or IDVs; subcontracting is immaterial (one sub-award out of 934). Biofire does not build delivery teams around subcontractors; it manufactures and ships its own diagnostic products directly to federal healthcare facilities. The company's primary NAICS footprint is in-vitro diagnostic substance manufacturing (577 awards), with secondary exposure in analytical laboratory instrument manufacturing (252 awards) and medical equipment repair and maintenance (41 awards), reflecting its equipment-lease and extended-warranty contracts.

Biofire Diagnostics has no named major subcontractors in its federal portfolio and does not appear to function as a feeder subcontractor to other large primes. It competes and operates as an independent original equipment manufacturer with proprietary diagnostic systems, selling directly to federal customers through GSA Schedule vehicles and negotiated BPAs. The company's market position rests on sole-source or original-equipment-manufacturer status for its FilmArray platform, enabling it to secure non-compete and extended-warranty maintenance contracts that anchor long-term customer relationships across the VA system and other federal health agencies.